Candida Esophagitis
Learn about Candida Esophagitis, also known as Esophageal Candidiasis or Candidal Esophagitis. This resource provides information on diagnosis, clinical documentation, and medical coding for healthcare professionals. Find details on ICD-10 codes, symptoms, treatment, and management of Candida Esophagitis for accurate and efficient clinical practice. Improve your medical coding and documentation with comprehensive insights into this esophageal condition.
Fungal infection of the esophagus caused by Candida species, typically Candida albicans.
Difficulty swallowing (dysphagia), pain with swallowing (odynophagia), and retrosternal chest pain. Mouth sores may be present.
Immunocompromised individuals (e.g., HIVAIDS, transplant recipients), diabetics, individuals on inhaled steroids.
ICD-10 Code Families
Complete code families applicable to B37.81
When to use each related code
| Description | When to use |
|---|---|
| Yeast infection of the esophagus. | Use for Candida infection specifically affecting the esophagus. Consider symptoms like painful swallowing. |
| General fungal infection of the esophagus. | Use when a fungal infection is present but Candida is not confirmed or other fungi are suspected. |
| Inflammation of the esophagus, non-infectious. | Use for esophageal inflammation not caused by infection, such as reflux esophagitis or eosinophilic esophagitis. |
Best-practice checklist
- ✓Document symptoms (dysphagia, odynophagia)
- ✓Endoscopy findings with location and extent of plaques
- ✓Confirmation method: biopsy, culture, or other
- ✓Differential diagnoses considered and ruled out
- ✓Treatment plan: antifungal medication, dosage, duration
Common pitfalls to avoid
Coding Candida esophagitis without specifying the esophagus can lead to inaccurate reimbursement and data analysis.
Incorrectly coding oral thrush (oral candidiasis) as esophageal candidiasis can lead to undercoding and lost revenue.
Failing to code associated HIV infection when present with Candida esophagitis can impact quality reporting and reimbursement.
Best-practice tips
- 01ICD-10 B37.8, optimize CDI for esophageal candidiasis.
- 02Prompt antifungal Rx, document response for compliance.
- 03Manage underlying conditions, improve coding specificity.
- 04Endoscopy with culture confirms diagnosis, aids CDI.
- 05Screen high-risk patients, document risk factors for HCC.
Step-by-step checklist
- 1
Immunocompromised status documented (ICD-10: B20-D89)?
- 2
Odynophagia or dysphagia present (ICD-10: R13.1)?
- 3
White plaques on endoscopy (SNOMED CT: 23417008)?
- 4
Positive fungal culture or smear (LOINC: 55410-3)?
Ready-to-paste narrative
Patient presents with complaints consistent with Candida esophagitis, also known as esophageal candidiasis or candidal esophagitis. Symptoms include odynophagia, dysphagia, retrosternal chest pain, and occasional nausea or vomiting. The patient reports difficulty swallowing, particularly with solid foods. Oral thrush was noted on examination. The differential diagnosis includes gastroesophageal reflux disease (GERD), esophageal spasm, and eosinophilic esophagitis. Given the clinical presentation and oral thrush, a diagnosis of Candida esophagitis is suspected. An esophagogastroduodenoscopy (EGD) with biopsy is recommended to confirm the diagnosis and rule out other esophageal pathologies. Treatment will be initiated with oral fluconazole, pending the EGD and biopsy results. Patient education provided on medication compliance, dietary modifications, and follow-up care. ICD-10 code B37.8 will be used for Candida esophagitis, with additional codes added if other conditions are identified. CPT codes for the EGD and biopsy will be determined upon procedure completion. This documentation supports medical necessity for the diagnostic and therapeutic interventions.
Common questions and answers
What are the most effective diagnostic approaches for differentiating Candida esophagitis from other esophageal disorders like GERD or eosinophilic esophagitis in immunocompetent adults?+
Differentiating Candida esophagitis from GERD and eosinophilic esophagitis in immunocompetent adults requires a multi-pronged approach. While symptoms can overlap, endoscopic evaluation with biopsy and histopathological examination for fungal elements remains the gold standard for confirming Candida esophagitis. In contrast, GERD diagnosis often relies on symptom assessment, response to PPI therapy, and endoscopic findings like erosions or strictures, whereas eosinophilic esophagitis diagnosis hinges on the presence of a significant eosinophilic infiltrate on esophageal biopsy. Furthermore, considering patient history (e.g., recent antibiotic use, inhaled corticosteroid use) and conducting a fungal culture from esophageal brushings or biopsies can contribute valuable information to reach a definitive diagnosis. Explore how integrating clinical presentation, endoscopic features, and laboratory results can improve the accuracy of differentiating these esophageal conditions. Consider implementing a diagnostic algorithm that incorporates both endoscopic and histopathologic assessment for optimal differentiation and treatment.
How does the management of Candida esophagitis differ in HIV-positive patients compared to non-HIV patients, specifically concerning initial antifungal choice, treatment duration, and secondary prophylaxis?+
Management of Candida esophagitis differs significantly between HIV-positive and non-HIV patients. In non-HIV patients, oral fluconazole is often the first-line treatment for uncomplicated cases, with a typical duration of 14-21 days. However, HIV-positive individuals, particularly those with advanced disease or low CD4 counts, may require more aggressive therapy with intravenous formulations like caspofungin initially, followed by a longer course of oral fluconazole. Secondary prophylaxis with fluconazole is often recommended for HIV-positive patients with recurrent esophagitis or persistent immune suppression to prevent relapse. Treatment duration and the decision to initiate secondary prophylaxis in HIV-positive patients should be individualized based on CD4 count, viral load, and clinical response. Learn more about the latest guidelines for managing opportunistic infections in HIV-positive individuals to tailor treatment approaches and optimize patient outcomes.
Beyond fluconazole, what alternative antifungal agents and treatment strategies are recommended for refractory or recurrent Candida esophagitis, and when should these alternatives be considered in clinical practice?+
For refractory or recurrent Candida esophagitis not responding to fluconazole, several alternative antifungal agents and treatment strategies are available. These include other azoles like itraconazole or voriconazole, echinocandins like caspofungin or micafungin, and amphotericin B formulations. Switching to an agent from a different class, such as an echinocandin, is often preferred in cases of fluconazole resistance. For severe or complicated cases, intravenous formulations may be necessary. Furthermore, addressing underlying predisposing factors, like uncontrolled diabetes or immunosuppression, is crucial. Consider implementing a step-up approach, starting with less toxic agents like oral fluconazole and escalating to more potent alternatives based on clinical response and patient-specific factors. Explore how combination antifungal therapy or prolonged treatment durations can be utilized in complex cases of refractory esophagitis under expert guidance.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.